The mucosal atomization device market is projected to grow from USD 570.52 million in 2024 to USD 1.11 billion by 2034, at a CAGR of 6.9%. Growth is driven by the increasing demand for non-invasive ...
The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic ...
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression ...